Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Welcome to Travere Therapeutics
Global Medical Affairs

At Travere Therapeutics Global Medical Affairs,
we are dedicated to sharing scientific knowledge, collaborating with experts,
and innovation for improved rare disease outcomes.

Decorative image
Travere at ASN Kidney Week 2025

American Society of Nephrology (ASN) Kidney Week 2025

Kidney Week 2025 is the annual meeting of the American Society of Nephrology (ASN). Travere Therapeutics was excited to participate in ASN Kidney Week 2025 and engage with nephrology leaders from around the world.

MA-DS-25-0077 | November 2025

Decorative Image

New 2025 IgAN/IgAV Guidelines from KDIGO

On September 18, 2025, the Kidney Disease Improving Global Outcomes (KDIGO) organization released the KDIGO 2025 Clinical Practice Guideline for the Management of IgA Nephropathy and IgA Vasculitis.

Marking a turning point in glomerular disease care, the new guidelines incorporate evidence from randomized controlled trials through August 2024.

MA-DS-25-0096 | September 2025

Risk Evaluation and Mitigation Strategies (REMS) Update for Sparsentan

On August 27, 2025, the Risk Evaluation and Mitigation Strategies (REMS) requirements for sparsentan were updated to reduce the frequency of liver function monitoring to every three months and to remove the embryo-fetal toxicity REMS monitoring requirement.

For more information, please read the US Prescribing Information.

MA-SP-25-0127 | September 2025

GlomCon Hawaii 2025
Travere at GlomCon Hawaii 2025

GlomCon Hawaii 2025

GlomCon Hawaii is the annual conference of the GlomCon Foundation. Travere Therapeutics was honored to participate and engage with clinicians, researchers, and nephrology experts from around the world.

MA-DS-25-0086 | September 2025

Decorative image
Webinar

The Dual Impact of Sparsentan on Inflammation and Proteinuria in IgA Nephropathy

Travere partnered with GlomCon on one of their Clinical Trial Series webinars. This webinar focused on sparsentan in IgA nephropathy.

MA-SP-25-0139 | November 2025

Our Latest Publications

Group of People
Publications Nephrology

Efficacy and Safety of Sparsentan Versus Irbesartan in Patients with IgA Nephropathy (PROTECT): 2-Year Results From a Randomised Active-Controlled Phase 3 Trial

The Lancet
2023

Learn more

Latest Podcast Episode

View all publications

Upcoming Events

Recent posters & presentations

e-Poster

Patients in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often With Sparsentan vs Irbesartan: Implications for Slowing Progression to Kidney Failure in Focal Segmental Glomerulosclerosis (FSGS)
e-Poster

Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy (IgAN): Interim Analysis of the SPARTAN Trial
e-Poster

Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT
View all event materials

Find an MSL

Find and connect your local Medical Science Liaison (MSL) for support related to Travere products.

Find your MSL

Search for Medical Information

Have questions?
Find scientific, evidence-based, and balanced information about Travere products.

Start a search